cytarabine has been researched along with valproic acid in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.45) | 18.2507 |
| 2000's | 9 (31.03) | 29.6817 |
| 2010's | 19 (65.52) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Armata, J; Bogusławska-Jaworska, J; Chybicka, A; Eliasińska, A; Jackowska, T; Klus, K; Kowalczyk, J; Kołecki, P; Krauze, A; Matysiak, M; Pietras, W; Rokicka-Milewska, R; Stefańska, K; Wiśniewska-Slusarz, H; Wójcik, D | 1 |
| Abe, T; Hori, S; Kawashima, H; Mori, T; Morikawa, N; Takeyama, M | 1 |
| Chaoui, D; Faussat, AM; Legrand, O; Majdak, P; Marie, JP; Perrot, JY; Tang, R | 1 |
| Koistinen, P; Savolainen, ER; Siitonen, T | 1 |
| Gattermann, N; Germing, U; Giagounidis, A; Haas, R; Kobbe, G; Kündgen, A; Nachtkamp, K; Strupp, C | 1 |
| Santini, V | 1 |
| Li, YQ; Ma, LP; Nie, DN; Wang, XJ; Wu, YD; Xie, SF; Yin, SM | 1 |
| Procházka, M; Procházka, V; Urbánek, K; Vinklerová, I | 1 |
| Buck, SA; Edwards, H; Ge, Y; Matherly, LH; Rubnitz, JE; Stout, ML; Taub, JW; Xie, C; Xu, X; Yu, Q; Zhou, H | 1 |
| Czemerska, M; Grzybowska-Izydorczyk, O; Pluta, A; Robak, T; Szmigielska-Kapłon, A; Wierzbowska, A; Wolska, A | 1 |
| Alvaro, MG; Baraldi, A; Ciravegna, G; Corsetti, MT; De Paoli, L; Gatto, S; Levis, A; Perticone, S; Pietrasanta, D; Pini, M; Primon, V; Salvi, F; Tonso, A; Zallio, F | 1 |
| Kuendgen, A | 1 |
| Fan, HM; Gill, D; Keane, C; Lane, S; McMillan, NA; Mollee, P; Murphy, R; Saunders, N; Spurr, T | 1 |
| Bruserud, O; Fredly, H; Gjertsen, BT; Reikvam, H | 1 |
| Buck, SA; Edwards, H; Ge, Y; Lograsso, SB; Matherly, LH; Taub, JW; Xie, C | 1 |
| Garcia-Manero, G; Sampath, D | 1 |
| Bruserud, Ø; Gjertsen, BT; McCormack, E; Mujić, M; Osdal, T | 1 |
| Brossart, P; Brugger, W; Derigs, HG; Döhner, H; Döhner, K; Gaidzik, VI; Göttlicher, M; Götze, K; Greil, R; Heil, G; Held, G; Horst, HA; Kirchen, H; Köhne, CH; Koller, E; Kremers, S; Matzdorff, A; Nachbaur, D; Paschka, P; Raghavachar, A; Ringhoffer, M; Schlenk, RF; Tassara, M; Wattad, M; Wulf, G | 1 |
| Brenner, AK; Bruserud, Ø; Ersvaer, E; Reikvam, H; Vetås, K | 1 |
| Cheng, H; Gao, L; Hu, X; Liu, N; Tang, G; Wang, C; Wang, J; Wang, L | 1 |
| Balleari, E; Bernal, T; Beyne-Rauzy, O; Bordessoule, D; Calabuig, M; Cametti, G; Campelo, MD; Cheze, S; Cony-Makhoul, P; Dreyfus, F; Fenaux, P; Fensterl, J; Ferrero, D; Gaidano, G; Germing, U; Gioia, D; Götze, K; Guerci-Bresler, A; Hamel, JF; Kaivers, J; Kelaidi, C; Komrokji, R; Kotsianidis, I; Müller-Thomas, C; Pane, F; Park, S; Ramos, F; Roboz, GJ; Rose, C; Sanna, A; Santini, V; Sanz, GF; Sapena, R; Sekeres, MA; Stamatoullas, A; Steensma, DP; Thépot, S; Toma, A; Vey, N; Wattel, E | 1 |
| Bruserud, Ø; Fredly, HK; Gjertsen, BT; Grønningsæter, IS; Hatfield, KJ | 1 |
2 review(s) available for cytarabine and valproic acid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.
Topics: Adenine Nucleotides; Animals; Arabinonucleosides; Azacitidine; Benzamides; Clofarabine; Cytarabine; Cytosine; Daunorubicin; Decitabine; Dioxolanes; Farnesyltranstransferase; Histone Deacetylase Inhibitors; Humans; Hydrazines; Imatinib Mesylate; Leukemia, Myeloid, Acute; Liposomes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases; Valproic Acid; Vascular Endothelial Growth Factor Receptor-1 | 2011 |
5 trial(s) available for cytarabine and valproic acid
| Article | Year |
|---|---|
[Treatment outcome for myelodysplastic syndromes (MDS) obtained by the Polish Children's Leukemia/Lymphoma Study Group].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Infant; Male; Mercaptopurine; Myelodysplastic Syndromes; Treatment Outcome; Valproic Acid | 1998 |
Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Anticonvulsants; Antimetabolites, Antineoplastic; Cytarabine; Drug Therapy, Combination; Feasibility Studies; Female; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Survival Rate; Treatment Outcome; Valproic Acid | 2011 |
Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activity.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Cytarabine; Drug Evaluation, Preclinical; Female; Humans; Leukemia, Myeloid, Acute; Male; Primary Cell Culture; Treatment Outcome; Tumor Cells, Cultured; Valproic Acid | 2012 |
Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytokines; Female; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Neoplasm Proteins; Palliative Care; Prognosis; Theophylline; Tretinoin; Tumor Cells, Cultured; Valproic Acid | 2012 |
Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Critical Care; Cytarabine; Disease-Free Survival; Drug Synergism; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Survival Rate; Tretinoin; Valproic Acid | 2014 |
22 other study(ies) available for cytarabine and valproic acid
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Pharmacokinetics of cytosine arabinoside, methotrexate, nimustine and valproic acid in cerebrospinal fluid during cerebrospinal fluid perfusion chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality Therapy; Cytarabine; Female; Glioblastoma; Humans; Methotrexate; Nimustine; Valproic Acid | 2000 |
Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1.
Topics: Acute Disease; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Division; Cell Line, Tumor; Cytarabine; Drug Evaluation, Preclinical; Drug Resistance, Multiple; Drug Synergism; Enzyme Inhibitors; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid; Multidrug Resistance-Associated Proteins; Tumor Cells, Cultured; Valproic Acid | 2004 |
Increase in Ara-C cytotoxicity in the presence of valproate, a histone deacetylase inhibitor, is associated with the concurrent expression of cyclin D1 and p27(Kip 1) in acute myeloblastic leukemia cells.
Topics: Butyrates; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p27; Cytarabine; Enzyme Inhibitors; Etoposide; Histone Deacetylase Inhibitors; Humans; Leukemia, Myeloid, Acute; Valproic Acid | 2005 |
Impact on survival of different treatments for myelodysplastic syndromes (MDS).
Topics: Adult; Aged; Antilymphocyte Serum; Cytarabine; Disease-Free Survival; Enzyme Inhibitors; Female; Germany; Humans; Immunosuppressive Agents; Male; Middle Aged; Myelodysplastic Syndromes; Registries; Retrospective Studies; Risk Factors; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Homologous; Valproic Acid | 2009 |
Is survival enough for myelodysplastic syndromes?
Topics: Adult; Aged; Antilymphocyte Serum; Cytarabine; Disease-Free Survival; Enzyme Inhibitors; Female; Germany; Humans; Immunosuppressive Agents; Male; Middle Aged; Myelodysplastic Syndromes; Registries; Retrospective Studies; Risk Factors; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Homologous; Valproic Acid | 2009 |
[Effect of valproic acid on the expression of P27(Kip1) and P170 and drug resistance of HL-60/HT cells].
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Cyclin-Dependent Kinase Inhibitor p27; Cytarabine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Glycoproteins; HL-60 Cells; Humans; Intracellular Signaling Peptides and Proteins; Valproic Acid | 2009 |
Incidence, severity, and etiology of drug-induced acute pancreatitis.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Child; Child, Preschool; Crohn Disease; Cytarabine; Dexamethasone; Female; Humans; Immunosuppressive Agents; Incidence; Male; Mesalamine; Middle Aged; Mycophenolic Acid; Pancreatitis; Ramipril; Retrospective Studies; Risk Factors; Severity of Illness Index; Valproic Acid; Young Adult | 2010 |
Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia.
Topics: Apoptosis; Caspase 3; Caspase 9; Cytarabine; DNA Damage; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Male; Structure-Activity Relationship; Tumor Cells, Cultured; Valproic Acid | 2010 |
An inexpensive way to treat elderly patients with high-risk MDS or AML.
Topics: Anemia, Refractory, with Excess of Blasts; Anticonvulsants; Antimetabolites, Antineoplastic; Cytarabine; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Remission Induction; Treatment Outcome; Valproic Acid | 2011 |
Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells.
Topics: Adenine Nucleotides; Adolescent; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Cell Line, Tumor; Child; Child, Preschool; Clofarabine; Cytarabine; DNA Damage; Drug Screening Assays, Antitumor; Drug Synergism; Female; Histone Deacetylase Inhibitors; Humans; Infant; Leukemia, Myeloid, Acute; Male; Tumor Cells, Cultured; Valproic Acid | 2012 |
Therapy for older patients with acute myeloblastic leukemia: a problem in search of a solution.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Valproic Acid | 2012 |
Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia.
Topics: Animals; Anthracyclines; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; CD11b Antigen; CD11c Antigen; Cell Line, Tumor; Cytarabine; Fluorescent Dyes; Green Fluorescent Proteins; HL-60 Cells; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Luminescent Measurements; Mice; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Optical Imaging; Tretinoin; Valproic Acid; Xenograft Model Antitumor Assays | 2013 |
Effects of cytarabine on activation of human T cells - cytarabine has concentration-dependent effects that are modulated both by valproic acid and all-trans retinoic acid.
Topics: ADP-ribosyl Cyclase 1; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; CD4 Antigens; CD8 Antigens; Cell Membrane; Cell Proliferation; Cell Survival; Cells, Cultured; Cytarabine; Cytokines; Dose-Response Relationship, Drug; Drug Interactions; Fas Ligand Protein; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Lectins, C-Type; Lymphocyte Activation; T-Lymphocytes; TNF-Related Apoptosis-Inducing Ligand; Tretinoin; Valproic Acid | 2015 |
Valproic acid enhances the antileukemic effect of cytarabine by triggering cell apoptosis.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Bone Marrow Cells; Cell Line; Cell Proliferation; Cytarabine; Disease Models, Animal; Drug Combinations; Drug Synergism; Enzyme Inhibitors; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid, Acute; Mice; Monocytes; Primary Cell Culture; Signal Transduction; Survival Analysis; Valproic Acid | 2016 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cyclosporine; Cytarabine; Decitabine; Disease Progression; Enzyme Inhibitors; Erythrocyte Transfusion; Female; Hematinics; Humans; Hydroxyurea; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Treatment Failure; Tretinoin; Valproic Acid | 2017 |
Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy.
Topics: Aged; Aged, 80 and over; Amino Acids; Cytarabine; Drug Therapy; Female; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Lipid Metabolism; Male; Mercaptopurine; Metabolomics; Middle Aged; Treatment Outcome; Tretinoin; Valproic Acid | 2019 |